Browsing Tag
Roche
101 posts
Roche’s enicepatide delivers 15.5% weight loss in type 2 diabetes Phase II trial
The once-weekly GLP-1 and GIP medicine also brought blood sugar into the normal range for 62% of patients at its highest dose, supporting plans for broader Phase III development in 2027.
Roche’s $570m MediLink bet gets Phase III validation as Tam-Peli cuts small-cell lung cancer death risk by 54%
MediLink Therapeutics' Tam-Peli improved median survival to 13.3 months from 9.4 months in relapsed small-cell lung cancer, giving Roche stronger clinical support for a programme that already carries $570 million of upfront and near-term economics.
Roche gets January FDA date for Enspryng after cutting MOGAD relapse risk 68%
Roche has secured FDA Priority Review for Enspryng in MOGAD after Phase 3 data showed a 68% reduction in relapse risk, with a U.S. decision due by January 10, 2027.
Elecsys pTau217 wins FDA clearance as Roche pushes Alzheimer’s testing into primary care
Roche has secured FDA clearance for Elecsys pTau217, giving more than 4,500 existing U.S. cobas analyzers a potential role in assessing Alzheimer’s amyloid pathology through a routine blood draw.
Novartis gains another potential MS growth engine after remibrutinib beats teriflunomide in two Phase III trials
Novartis shares surge after remibrutinib wins two Phase III MS trials, opening another potential growth opportunity alongside Kesimpta.
Chemomab Therapeutics (CMMB) and Scipher Medicine to merge in $150m reverse deal
Scipher Medicine and Chemomab are merging in all-stock deal, taking Scipher public via reverse merger. $30M PIPE led by Northpond. Q4 2026 close, H1 2028 Phase 2 data.
Bionyra raises $165m to build an immunology company from licensed assets
Bionyra launches with $165 million and three licensed immunology drugs. Read how its portfolio-first model could reshape biotech company creation.
Abivax (NASDAQ: ABVX) obefazimod NDA path meets a safety debate the market is still pricing
Abivax (NASDAQ: ABVX) put up Rinvoq-like ulcerative colitis remission data and dropped 40 percent. The question is whether the malignancy debate sticks.
Replimune (REPL) soars 86% as WSJ says White House intervention reopens RP1 review
Replimune jumped nearly 86% after the WSJ reported White House officials pushed the FDA to reconsider twice-rejected RP1. A reopened path, and a binary bet on approval.
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?